| Name | Title | Contact Details |
|---|
Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for kidney disease. Just as the goldfinch was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney disease. Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. Our Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets to treat progressive kidney disease. At Goldfinch, we`re pioneering a new approach to discover and develop therapeutics that target the molecular basis of kidney disease. We`re looking for teammates who relish the challenge, and are compelled to leave a positive mark on the lives of colleagues and patients alike.
Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company’s proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company’s website
Adare Pharma Solutions is a global contract development and manufacturing organization (CDMO) focused on oral dosage forms for the pharmaceutical industry. The company offers integrated services that span from product development to commercial manufacturing and packaging, with a strong emphasis on small molecule pharmaceuticals. With around 800 employees and seven facilities in the United States and Europe, Adare is well-equipped to serve markets worldwide. The company specializes in technologies such as taste masking, customized release, and solubility enhancement, addressing unique formulation challenges. Adares product development services include formulation development, analytical method validation, and support for various regulatory submissions. Their manufacturing capabilities encompass a range of processes, including granulation, coating, and high potency manufacturing. Additionally, Adare operates a dedicated packaging facility that provides high-speed packaging solutions. The company serves a diverse customer base, including branded, specialty, generic, and veterinary pharmaceutical segments, and is committed to maintaining high regulatory standards across all operations.
The science of co-creation drives our quest to engineer life-changing immunology solutions, the resilient spirit of patients fuels our urgency to deliver them.
Novus Therapeutics, Inc. (NASDAQ: NVUS) is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease.